Solid Biosciences Inc. (SLDB) shares surged more than 31% on Tuesday, their best session since January 2024, and extended ...

MUSC health has established the Rena N. Grant Sickle Cell Center to help treat those suffering from sickle cell disease. This ...

A 31-year-old Sligo man who was functionally blind has got his sight back, after being treated with a new gene therapy at the ...

D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential. Click here to find out why I rate ...

The Medical University of South Carolina is expanding its access to state-supported Sickle Cell programs for “warriors,” or ...

An SCD patient in Bahrain received the gene-editing therapy Casgevy, marking the first time the treatment has been given outside the U.S.

Solid Biosciences shares were up 50% to $6.06 after the company said it saw positive initial data from a Phase 1/2 trial evaluating SGT-003, a gene therapy product candidate intended for the treatment ...

The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.

Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of ...

Solid said that the first patients to receive its Duchenne gene therapy all produced high levels of the target protein, an ...

New 12-month data on the first three adult OPGx-LCA5 patients to be presented at a major medical conference in Q2 2025 FDA meeting scheduled in March 2025 to discuss Phase 3 trial design and ...

Why did humans start speaking? Scientists suggest genetics played a big role. They say the evolution of this singular ability ...